Qatar Blood Gas & POC Immunoassay Analyzer Market is currently in its Growing Stage Owing to a rise in Health Infrastructure & technological Innovations: Ken Research

1. Reagent price and type of device are the predominant factor that are influencing the growth of BGA devices amongst healthcare facility in Qatar

When it comes to BGA segment in Qatar's Blood Gas & POC Immunoassay Analyzer Market, the ecosystem is well positioned with a limited number of players operating in the market. These players are competing on the basis of cost per test, testing parameters, design and portability of the product and friendly user interface. Moreover, there is no obstacle in the regulation of devices except the product needs to be registered with Pharmacy and Drug Control Department. It is also assumed that private sector is better positioned to introduce new devices as compared to public hospitals. BGA Market is also mature & saturated in the private sector.

To Know More about this report, download a Free Sample Report @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTc0NDQx

Furthermore, a number of challenges such as limited reagent shelf life, no device installed in independent labs due to no demand for these testing parameters in such facilities can hinder the growth in upcoming years. When it comes to exploring private sector, increased partnership between private and public sector to improve the healthcare infrastructure will help the diagnostic equipment market to grow and Public-private partnerships is also expected to ease economic burden of non-communicable diseases on government spending. It is expected that in the upcoming years, installed base for BGA devices is expected to grow at a CAGR 6.4% (2021-2026F) reaching 172 devices in 2026 with transition in the market, high preference for POC devices serving as growth drivers.

2. POC Benchtop Immunoassay penetration in Qatar is extremely low since the introduction of POC handheld devices as an alternative

To Know More about industry trends, Request a free 30 Min Expert call @ https://www.kenresearch.com/talk-to-expert.php

The number of POC IAA installed devices is expected to witness an increase in the upcoming years. Emerging economy offer significant growth opportunities for the players operating in this market. There would be a high need for rapid daily testing especially for the cardiac parameter in the future, which will result in the high demand for POC IAA in hospitals. A series of challenges are expected to hinder the growth if not taken care of properly.

For instance, Immunoassay is not preferred in Qatar, hospitals collect samples and send it to the centralized lab IAA because these devices have a testing capacity in bulk. Moreover, POC devices are not included for Immunoassay's guidelines of health as of now by Qatari Government which possess a major issue for the POC device inclusion in the country.

3. Compared to other GCC Countries Qatar has a high installation of the TCM devices, however the no. of players are very limited

Visit this Link Request for a custom report @ https://www.kenresearch.com/ask-customization.php?Frmdetails=NTc0NDQx

The TCM market is expected to grow @12.9% CAGR (2021-26F) in the coming years with Radiometer and Sentec being the market leaders in the country. When it comes to future growth drivers, the competitive pricing offered by major manufacturers would increase demand for TCM devices. For example, in Qatar, Sentec offers lower prices for the devices. Moreover, innovative products & their reliability are also expected to serve as growth drivers.

For more insights on market intelligence, refer to the link below: -
https://www.kenresearch.com/healthcare/medical-devices/qatar-blood-gas-analyzer-poc-immunoassay-analyzer-transcutaneous-monitors-market/574441-91.html

SECTOR 49

Ken Research is a Market Research and Consulting Firm, based out of India, Indonesia and UAE. Since 2011, we have been assisting clients globally with our Syndicate and Bespoke Market Research and Advisory Services.

This release was published on openPR.